UK Zocor Experience Inadequate To Sway FDA Panel On Mevacor
This article was originally published in The Tan Sheet
J&J/Merck could have benefited from a minimum of one-year UK consumer-use data of 10 mg simvastatin before facing a panel with its lovastatin 20 mg switch proposal in the U.S
You may also be interested in...
A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists
Customers who present at UK pharmacies to purchase McNeil Europe's Zocor Heart-Pro (simvastatin 10 mg) without a prescription will need to disclose risk factors such as age and family history of heart disease, but not necessarily their cholesterol level, under a marketing plan cleared by the UK health agency
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC